PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Human genome was shaped by an evolutionary arms race with itself

New study of primate genomes reveals an ongoing battle to control 'jumping genes,' driving the evolution of greater genomic complexity

Human genome was shaped by an evolutionary arms race with itself
2014-09-28
(Press-News.org) New findings by scientists at the University of California, Santa Cruz, suggest that an evolutionary arms race between rival elements within the genomes of primates drove the evolution of complex regulatory networks that orchestrate the activity of genes in every cell of our bodies.

The arms race is between mobile DNA sequences known as "retrotransposons" (a.k.a. "jumping genes") and the genes that have evolved to control them. The UC Santa Cruz researchers have, for the first time, identified genes in humans that make repressor proteins to shut down specific jumping genes. The researchers also traced the rapid evolution of the repressor genes in the primate lineage.

Their findings, published September 28 in Nature, show that over evolutionary time, primate genomes have undergone repeated episodes in which mutations in jumping genes allowed them to escape repression, which drove the evolution of new repressor genes, and so on. Furthermore, their findings suggest that repressor genes that originally evolved to shut down jumping genes have since come to play other regulatory roles in the genome.

"We have basically the same 20,000 protein-coding genes as a frog, yet our genome is much more complicated, with more layers of gene regulation. This study helps explain how that came about," said Sofie Salama, a research associate at the UC Santa Cruz Genomics Institute who led the study.

Retrotransposons are thought to be remnants of ancient viruses that infected early animals and inserted their genes into the genome long before humans evolved. Now they can only replicate themselves within the genome. Depending on where a new copy gets inserted into the genome, a jumping event can disrupt normal genes and cause disease. Often the effect is neutral, simply adding to the overall size of the genome. Very rarely the effect might be advantageous, because the added DNA can itself be a source of new regulatory elements that enhance gene expression. But the high probability of deleterious effects means natural selection favors the evolution of mechanisms to prevent jumping events.

Scientists estimate that jumping genes or "transposable elements" account for at least 50 percent of the human genome, and retrotransposons are by far the most common type.

"There have been successive waves of retrotransposon activity in primate evolution, when a transposable element changed to become expressed and replicated itself throughout the genome until something turned it off," Salama said. "We've discovered a major mechanism by which the genome is able to shut down these mobile DNA elements."

The repressors identified in the new study belong to a large family of proteins known as "KRAB zinc finger proteins." These are DNA-binding proteins that repress gene activity, and they constitute the largest family of gene-regulating proteins in mammals. The human genome has over 400 genes for KRAB zinc finger proteins, and about 170 of them have emerged since primates diverged from other mammals.

According to Salama, her team's findings support the idea that expansion of this family of repressor genes occurred in response to waves of retrotransposon activity. Because repression of a jumping gene also affects genes located near it on the chromosome, the researchers suspect that these repressors have been co-opted for other gene-regulatory functions, and that those other functions have persisted and evolved long after the jumping genes the repressors originally turned off have degraded due to the accumulation of random mutations.

"The way this type of repressor works, part of it binds to a specific DNA sequence and part of it binds other proteins to recruit a whole complex of proteins that creates a repressive landscape in the genome. This affects other nearby genes, so now you have a potential new layer of regulation available for further evolution," Salama said.

KRAB zinc finger proteins are the subject of intensive research as scientists try to sort out their many regulatory roles within the genome. The idea that they are involved in repression of jumping genes is not new--previous studies by other researchers have shown that these proteins silence jumping genes in mouse embryonic stem cells. But until now, no one had been able to demonstrate that the same thing occurs in human cells.

The UC Santa Cruz team developed a novel assay to test whether a particular KRAB zinc finger protein could shut down certain jumping genes. The first authors of the paper, postdoctoral researcher Frank Jacobs and graduate student David Greenberg, came up with the strategy of testing primate retrotransposons in non-primate cells by using mouse embryonic stem cells that contain a single human chromosome. In the environment of a mouse cell, jumping genes that were repressed in primate cells became active. Greenberg then developed an assay for testing individual zinc finger proteins for their ability to turn off a primate jumping gene in the mouse cell environment.

"We did all our tests in mouse cells because they lack all of the primate zinc finger proteins, so when you put primate retrotransposons into a mouse cell they're all active," Salama explained.

The results demonstrated that two human proteins called ZNF91 and ZNF93 bind and repress two major classes of retrotransposons (known as SVA and L1PA) that are currently or recently active in primates. Assistant research scientist Benedict Paten directed graduate student Ngan Nguyen in a painstaking analysis of primate genomes, including the reconstruction of ancestral genomes, which showed that ZNF91 underwent structural changes 8 to 12 million years ago that enabled it to repress SVA elements.

Experiments with ZNF 93, which shuts down L1PA retrotransposons, provided a striking illustration of the arms race between jumping genes and repressors. The researchers found that, while it is good at shutting down many L1PA elements, there is one subset of a recently evolved lineage of L1PA that has lost a short section of DNA that includes the ZNF93 binding site. Without the binding site, these jumping genes evade repression by ZNF93. Interestingly, when the researchers put the missing sequence back into one of these genes and put it in a mouse cell without ZNF93, they found that it was better at jumping. So even though the sequence helps with jumping activity, losing it gives the jumping gene an advantage in primates by allowing it to escape repression by ZNF93.

"That's kind of the icing on the cake for aficionados of molecular evolution, because it demonstrates that this is a never-ending race," Salama said. "KRAB zinc finger proteins are a rare class of proteins that is rapidly expanding and evolving in mammalian genomes, which makes sense because the transposable elements are themselves continually evolving to escape repression."

Corresponding author David Haussler, professor of biomolecular engineering and director of the UC Santa Cruz Genomics Institute, said the study involved close collaboration between his group's "wet lab," directed by Salama, and the "dry lab" where researchers under Paten's direction used the computational tools of genome bioinformatics to reconstruct the evolutionary history of primate genomes. Haussler, a Howard Hughes Medical Institute investigator who has used his background in computer science to do pioneering work in genomics, said he established the wet lab to enable just this kind of collaboration.

"Both parts were integral to this study, and there was a lot of back and forth between them. This paper shows how important it is to integrate computational and experimental approaches to fundamental scientific problems, such as how and why we continuously evolve to be more complex," Haussler said.

INFORMATION:

In addition to Jacobs, Greenberg, Paten, Nguyen, Salama, and Haussler, the coauthors of the paper include postdoctoral researchers Maximilian Haeussler and Adam Ewing; and sequencing analyst Sol Katzman. This work was supported by the California Institute for Regenerative Medicine, Human Frontier Science Program, National Institutes of Health, and Howard Hughes Medical Institute.

[Attachments] See images for this press release:
Human genome was shaped by an evolutionary arms race with itself

ELSE PRESS RELEASES FROM THIS DATE:

Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous Lu Ca

2014-09-27
The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events. At the ESMO 2014 Congress in Madrid, Dr Young-Chul Kim from Chonnam National University Medical School, South Korea, reported the results of an open-label phase III trial that included 149 patients with non-squamous non-small cell lung cancer (NSCLC) conducted at 14 centres in South Korea. "We wanted ...

Customising chemotherapy in Lu Ca: New Ph II data reported in 2 LB studies

2014-09-27
Measuring the expression levels of an enzyme involved in DNA synthesis can help predict the response of lung cancers to certain treatments, a Korean study has shown at the ESMO 2014 Congress in Madrid. In a randomized phase II study, researchers showed that patients whose lung cancers expressed low levels of an enzyme called thymidylate synthase experienced a greater benefit from treatment with the combination of pemetrexed and cisplatin than those whose tumours expressed high levels. "Thymidylate synthase is one of the proteins that is targeted by pemetrexed which ...

French studies measure benefits of colorectal cancer screening

2014-09-27
The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk pre-cancerous adenomas (sometimes called polyps) by 89%, researchers have reported at the ESMO 2014 Congress in Madrid. Dr Vanessa Cottet from INSERM Unité 866 in Dijon, France, and colleagues studied the region of Côte-d'Or, where a registry has been collecting data on adenomas since 1976. They wanted to evaluate the rate of diagnosis of adenomas before and after the initiation of a screening program using fecal occult blood testing that began ...

Crizotinib treatment effective against ROS1-positive lung cancer

2014-09-27
Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine to coincide with a presentation at the European Society for Medical Oncology meeting, an international research team reports that crizotinib treatment led to significant tumor shrinkage in 36 of 50 study participants and suppressed tumor growth in another 9. "Prior to this study, there were a handful of reports describing marked responses to crizotinib ...

Cancer during pregnancy: Chemotherapy and radiotherapy are safe for babies, studies show

2014-09-27
Children who are exposed to chemotherapy or radiotherapy while in the womb suffer no negative impacts on mental or cardiac development, international studies presented at the ESMO 2014 Congress in Madrid have shown. "When chemotherapy is administered after the first trimester of pregnancy, we cannot discern any problems in the children," says lead author Dr Frederic Amant, KU Leuven and University Hospitals Leuven in Belgium. "Fear about the risks of chemotherapy administration should not be a reason to terminate a pregnancy, delay cancer treatment for the mother, or ...

Anamorelin improve appetite and body mass in patients with cancer anorexia-cachexia

2014-09-27
A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. "Anorexia and cachexia are among the most troubling and distressing symptoms of advanced cancer, for both patients and their families," says the study's principal investigator, Dr Jennifer Temel from the Department of Medicine, Massachusetts General Hospital, Boston, USA. Symptoms of the wasting syndrome can include a loss of weight and muscles, ...

Afatinib improves progression-free survival in head and neck cancer

2014-09-27
The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show. Presented at the ESMO 2014 Congress in Madrid, the Lux-Head & Neck 1 trial showed that patients who received treatment with 40 mg/day oral afatinib had a 20% reduction in risk of progression or death compared to patients who received methotrexate, with a median progression-free survival of ...

Rolapitant reduces nausea and vomiting in Phase III trial

2014-09-27
Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain. Dr Martin Chasen, lead author and medical director, Palliative Care, Ottawa Hospital Cancer Centre, Canada, said: "This agent makes a significant difference in the way people tolerate their chemotherapy. Patients experienced no loss in quality of life and, in fact, many saw meaningful improvements. One of the patients in the rolapitant cohort reported that ...

Countries must work together to stop organ traffickers, says researcher

2014-09-27
The author of new research into organ trafficking has called for a concerted international effort to confront the problem. Dr Ana Manzano, of the School of Sociology and Social Policy at the University of Leeds, says a combination of factors means nobody knows definitively how many organs are being traded across the world. She said: "Unless these issues are addressed and countries work together to take firm action against the traffickers, more people who have their organs trafficked will die. "Even in the UK, although the World Health Organization has identified us ...

Smoke still rising from King Fire in California

Smoke still rising from King Fire in California
2014-09-26
Over 96,004 acres have been burned by the King Fire since it began on September 13, 2014. The fire is currently 68% contained, and the cause of the fire is arson. Just a few days ago, (Sept. 23) the fire was only 38% contained so progress on extinguishing it continues. Over 7,700 personnel are battling this fire. A Pacific system came through the fire area yesterday (9/25) bringing 0.6-0.9 inches of rain. The observed fire activity was minimal with smoldering in interior pockets of the heavier fuels. A low pressure system will become the dominate feature today (9/26) ...

LAST 30 PRESS RELEASES:

Multiple sclerosis drug may help with poor working memory

The MIT Press releases workshop report on the future of open access publishing and policy

Why substitute sugar with maple syrup?

New study investigates insecticide contamination in Minnesota’s water

The Einstein Foundation Berlin awards €500,000 prize to advance research quality

Mitochondrial encephalopathy caused by a new biallelic repeat expansion

Nanoplastics can impair the effect of antibiotics

Be humble: Pitt studies reveal how to increase perceived trustworthiness of scientists

Promising daily tablet increases growth in children with dwarfism

How 70% of the Mediterranean Sea was lost 5.5 million years ago

Keeping the lights on and the pantry stocked: Ensuring water for energy and food production

Parkinson’s Paradox: When more dopamine means more tremor

Study identifies strategy for AI cost-efficiency in health care settings

NIH-developed AI algorithm successfully matches potential volunteers to clinical trials release

Greg Liu is in his element using chemistry to tackle the plastics problem

Cocoa or green tea could protect you from the negative effects of fatty foods during mental stress - study

A new model to explore the epidermal renewal

Study reveals significant global disparities in cancer care across different countries

Proactively screening diabetics for heart disease does not improve long-term mortality rates or reduce future cardiac events, new study finds

New model can help understand coexistence in nature

National Poll: Some parents need support managing children's anger

Political shadows cast by the Antarctic curtain

Scientists lead study on ‘spray on, wash off’ bandages for painful EB condition

A new discovery about pain signalling may contribute to better treatment of chronic pain

Migrating birds have stowaway passengers: invasive ticks could spread novel diseases around the world

Diabetes drug shows promise in protecting kidneys

Updated model reduces liver transplant disparities for women

Risk of internal bleeding doubles when people on anticoagulants take NSAID painkiller

‘Teen-friendly’ mindfulness therapy aims to help combat depression among teenagers

Innovative risk score accurately calculates which kidney transplant candidates are also at risk for heart attack or stroke, new study finds

[Press-News.org] Human genome was shaped by an evolutionary arms race with itself
New study of primate genomes reveals an ongoing battle to control 'jumping genes,' driving the evolution of greater genomic complexity